Form 4: Viridian Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Christopher W. Cain acquired stock options in Viridian Therapeutics, Inc. on March 10, 2025.
Summary
- On March 10, 2025, Christopher W. Cain, a director of Viridian Therapeutics, Inc., acquired 42,000 stock options with an exercise price of $15.58.
- The options vest in 36 equal monthly installments, contingent upon continued service on the Board of Directors.
- The options expire on March 10, 2035.
- Cain holds the options for investment vehicles managed by Fairmount Funds Management LLC and will turn over any proceeds to them, disclaiming beneficial ownership.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.
Industry Context
This is a standard Form 4 filing, reflecting a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The transaction itself has minimal direct impact on stakeholders.
- It provides transparency to shareholders regarding director compensation.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of the stock option transaction. |
| 03/10/2025 | Stock options vest and become exercisable in 36 equal monthly installments. |
| 03/10/2035 | Expiration date of the stock options. |
| 03/12/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.